An Overview of CDK Enzyme Inhibitors in Cancer Therapy
Peddaguravagari Mounika1, Bannimath Gurupadayya1, Honnavalli Yogish Kumar1
1Department of Pharmaceutical Chemistry, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Mysuru, 570015, India.
Abstract:
The ability to address the cell cycle in cancer therapy brings up new medication development possibilities. Cyclin-dependent kinases are a group of proteins that control the progression of the cell cycle. The CDK/cyclin complexes are activated when specific CDK sites are phosphorylated. Because of their non-selectivity and severe toxicity, most first-generation CDK inhibitors (also known as pan-CDK inhibitors) have not been authorized for clinical usage. Despite this, significant progress has been made in allowing pan-CDK inhibitors to be employed in clinical settings. Pan-CDK inhibitors' toxicity and side effects have been lowered in recent years because of the introduction of combination therapy techniques. As a result of this, pan-CDK inhibitors have regained a lot of clinical potential as a combination therapy approach. The CDK family members have been introduced in this overview, and their important roles in cell cycle control have been discussed. Then, we have described the current state of CDK inhibitor research, with a focus on inhibitors other than CDK4/6. We have mentioned first-generation pan-CDKIs, flavopiridol and roscovitine, as well as second-generation CDKIs, dinaciclib, P276-00, AT7519, TG02, roniciclib, and RGB-286638, based on their research phases, clinical trials, and cancer targeting. CDKIs are CDK4/6, CDK7, CDK9, and CDK12 inhibitors. Finally, we have looked into the efficacy of CDK inhibitors and PD1/PDL1 antibodies when used together, which could lead to the development of a viable cancer treatment strategy.
Insights
Targeting the cell cycle with cyclin-dependent kinase (CDK) inhibitors shows promise in cancer therapy. Combination strategies are improving the safety and efficacy of these CDK inhibitors for clinical use.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- The cell cycle is a critical target for cancer therapy, with cyclin-dependent kinases (CDKs) regulating its progression.
- First-generation CDK inhibitors (pan-CDKIs) faced challenges due to non-selectivity and toxicity, limiting clinical application.
- Advancements in combination therapy have shown potential in mitigating the side effects of pan-CDKIs.
Purpose of the Study:
- To review CDK family members and their roles in cell cycle control.
- To summarize the current landscape of CDK inhibitor research, focusing on inhibitors beyond CDK4/6.
- To explore the combined efficacy of CDK inhibitors and PD1/PDL1 antibodies as a novel cancer treatment strategy.
Main Methods:
- Overview of CDK family members and their functions in cell cycle regulation.
- Review of first-generation pan-CDKIs (e.g., flavopiridol, roscovitine) and second-generation CDKIs (e.g., dinaciclib, P276-00).
- Analysis of research phases, clinical trials, and cancer targeting for various CDK inhibitors (CDK4/6, CDK7, CDK9, CDK12).
Main Results:
- Significant progress has been made in improving the clinical applicability of pan-CDK inhibitors through combination therapies.
- Several second-generation CDKIs are under investigation for various cancer types.
- Combination therapy of CDK inhibitors with PD1/PDL1 antibodies demonstrates potential for effective cancer treatment.
Conclusions:
- Pan-CDK inhibitors are regaining clinical potential, particularly when used in combination regimens.
- Targeting specific CDKs (CDK4/6, CDK7, CDK9, CDK12) offers a more refined therapeutic approach.
- The combination of CDK inhibitors and PD1/PDL1 antibodies represents a promising avenue for future cancer therapy development.
Related Concept Videos
02:34Inhibition of Cdk Activity
02:15M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
02:39Positive Regulator Molecules
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:38Mitogens and the Cell Cycle
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...